Surgical Oncologists as Scientists (SOAS) Training Program

项目总结/摘要 改善患者健康的转化癌症研究需要一种多学科的方法， 从（A）基础研究到（B）临床前验证（通常利用生物库组织）的创新发现， (C)通过创业和商业化实现临床实施。但外科医生很少接受正式的 在生物银行和企业家精神的培训，很少有计划被设计为正式培训外科医生在 癌症生物学和肿瘤微环境（TME）。认识到外科医生培训中的这些关键差距- 科学家，外科和摩尔癌症中心（NCI-Designated综合癌症中心） Center）和加州圣地亚哥大学（UC San Diego）外科系提出了一种新的 一项计划，以支持对医学博士/DO外科医生科学家的培训，这些医生科学家表现出致力于 职业生涯在学术外科肿瘤学为期两年的培训计划。我们将创建外科肿瘤学家 作为科学家（SOAS）培训计划集中在三个主题的正式培训：1）TME; 2）生物库; （3）创新/创业。TME培训的基本原理是，越来越多的肿瘤外科医生- 科学家需要彻底了解TME如何在癌症发生中发挥重要作用的细节， 进展、转移、对治疗的反应，并作为抗癌药物的新靶点。的理由 生物库培训的一个重要原因是，学术外科医生经常被要求在研究中合作， 他们对人类标本的无与伦比的获取，这些标本必须妥善储存在专门的生物储存库中。 最后，创新/创业培训的理由是，迫切需要确保 外科医生-科学家的研究培训具有现实世界的翻译相关性-也就是说，我们需要证明 改善癌症护理，而不仅仅是改善理解。这一基本原理利用了大都市圣地亚哥 作为成功平移所必需的第三大组件的面积（即，商业化） 将创新转化为食品和药物管理局（FDA）批准的临床现实。圣地亚哥有很多 生物技术创业公司（数百家从加州大学圣地亚哥分校分拆出来），天使投资人，私募股权和风险投资 公司、合同研究组织和地方网络活动。SOAS计划将由一个 外科肿瘤学家/翻译科学家和博士科学家，他们带来了互补但独特的技能， 创新的科学和经验。研究培训将在14个教师导师之一的 每个实验室都有坚实的，持续的R 01 NIH资金，每个实验室都有成功的记录。 导师制此外，学员将与我们的9个创业者中的至少一个建立共同指导关系。 联络顾问，每个人都有翻译方面的实际经验（例如，专利、初创企业）。SOAS 培训计划将培训合作外科医生科学家成为未来的领导者在学术手术和 积极参与将创新的新发现转化为临床癌症护理。

PROJECT SUMMARY / ABSTRACT Translational cancer research that improves patient health requires a multi-disciplinary approach that advances innovative discoveries from (A) basic research to (B) preclinical validation (often utilizing biobanked tissue) to (C) clinical implementation via entrepreneurship and commercialization. But surgeons rarely receive formal training in biobanking and entrepreneurship, and few programs are designed to formally train surgeons in the cancer biology and the tumor microenvironment (TME). Recognizing these critical gaps in training surgeon- scientists, the Department of Surgery and the Moores Cancer Center (NCI-Designated Comprehensive Cancer Center) and the Department of Surgery at the University of California San Diego (UC San Diego) propose a new program to support training for MD/DO surgeon-scientists who show objective evidence of a commitment to a career in academic surgical oncology for a two-year training program. We will create the Surgical Oncologists as Scientists (SOAS) Training Program centered on formal training in three topics: 1) the TME; 2) biobanking; and 3) innovation/entrepreneurship. The rationale for TME training is that increasingly, the oncologic surgeon- scientist needs to thoroughly understand details of how the TME plays significant roles in cancer initiation, progression, metastasis, response to therapies, and serves as novel targets for anti-cancer drugs. The rationale for training in biobanking is that academic surgeons are frequently asked to collaborate in research because their unparalleled access to human specimens, which must be properly banked in a dedicated biorepository. Finally, the rationale for innovation/entrepreneurship training involves the critical need to ensure that research training of surgeon-scientists has real-world translational relevance—that is, we need to demonstrably improve cancer care, not merely improve understanding. This rationale leverages the metropolitan San Diego area as the third largest assembly of components necessary to successfully translate (i.e., commercialize) innovations into Food and Drug Administration (FDA)-approved clinical realities. San Diego includes a plethora of biotech startups (hundreds spun out of UC San Diego), Angel investors, private equity and venture capital firms, contract research organizations, and local networking activities. The SOAS program will be co-led by a surgical oncologist/translational scientist and a PhD scientist that bring complementary, but unique skills in science and experience in innovation. Research training will occur within one of 14 Faculty Mentor’s laboratories, each of which has solid, continuous R01 NIH funding, and each has a strong record of successful mentorship. Also, Trainees will develop co-mentoring relationships with at least one of our 9 Entrepreneurial Liaison Advisors, each of whom has practical experience with translation (e.g., patents, start-ups). The SOAS Training Program will train collaborative surgeon-scientists to become future leaders in academic surgery and oncology to actively participate in translating innovative new discoveries into clinical cancer care.